European Lead Factory one of IMI’s most high-profile projects

Until now, the Innovative Medicines Initiative (IMI) has launched almost 100 projects to tackle the barriers that currently limit the efficiency, effectiveness and quality of medical research and drug development.

Spin-out Keapstone Therapeutics receives further funding

Based on the hits generated by the European Lead Factory, Dr Richard Mead, University of Sheffield, started the spin-out virtual biotech Keapstone Therapeutics, a world-first type of partnership between Parkinson's UK and the University of Sheffield. Keapstone Therapeutics aims to develop a new therapy for motor neurone disease (MND/ALS) and/or Parkinson’s disease.

ELF Chemistry event brings together scientists in Belgium

The European Lead Factory (ELF) acknowledges the need for open exchange between researchers with different professional backgrounds and puts a focus on the career development of young scientists. Therefore, the European Lead Factory annually invites young talented EU Lead Factory chemists from participating small and medium-sized enterprises (SMEs) and academic institutions to a so-called Learnings and Achievements meeting, where they can present their scientific work, interact with colleagues and liaise with representatives from participating established pharmaceutical companies and SME partners.

19 Successful career researchers!

The European Lead Factory congratulates 19 early career researchers that have been nominated to participate in the ELF Annual Chemistry Learning & Achievements meeting at the Janssen Campus (Janssen Pharmaceutica NV) in Beerse, Belgium, 6-7 November 2017!

EU-OPENSCREEN signs Memorandum of Understanding

The European infrastructure EU-OPENSCREEN and the European Lead Factory executives of the European Screening Centre and the Public Chemistry Consortium have signed a Memorandum of Understanding for collaboration in future initiatives.

Follow us at

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n' 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution.